Psychedelics

Nichols, David E.

doi:10.1124/pr.115.011478

Cited by 1,214 publications

(1,462 citation statements)

References 589 publications

Supporting

Mentioning

1,265

Contrasting

Unclassified

Order By: Relevance

“…Despite these important limitations, many of the results seem to be consistent among different studies 21,25,26,36 , and recent studies with other hallucinogenic compounds that also act as serotonin 5-HT 2A receptor agonists, such as psilocybin and LSD, further support these findings 8,25,26,36,53 . Nevertheless, it is important to highlight the fact that some of these studies share the same limitations as those observed in ayahuasca studies, especially regarding small sample sizes and lack of a double-blind design 31,45,50,51 .…”

Section: Limitations Of the Studiesmentioning

confidence: 60%

“…However, the β-carbolines in the vine reversibly inhibit MAO-A and allow DMT to reach the Central Nervous System [4][5][6] . The main mechanism of action of DMT appears to partial agonism on serotonergic 2A (5-HT 2A ) receptors expressed on layer V cortical neurons, a process that also seems to involve metabotropic glutamate receptors (mGluR) 7,8 . DMT is an endogenous compound, although its physiological functions are not known 9,10 .…”

Section: Botany Chemistry and Mechanism Of Actionmentioning

confidence: 99%

“…DMT is an endogenous compound, although its physiological functions are not known 9,10 . There is some evidence that endogenous DMT could act as a neurotransmitter on sigma receptors 11,12 , but human studies suggest that the psychoactive effects of classic/serotonergic hallucinogens such as lysergic acid diethylamide (LSD), psilocybin and DMT are mainly mediated by the 5-HT 2A receptor 8,[13][14][15] . photon emission computed tomography (SPECT), and structural and functional magnetic resonance imaging (MRI and fMRI, respectively).…”

Section: Botany Chemistry and Mechanism Of Actionmentioning

confidence: 99%

“…Classic or serotonergic hallucinogens including LSD, psilocybin, mescaline and DMT are considered drugs with low physiological toxicity that can be safely administered in controlled settings, including both ritual and experimental/clinical contexts 8,17,25,26,36,52,53 . Recent human studies involving acute administration of LSD and psilocybin to healthy volunteers and to patients with drug dependence or anxiety and mood disorders show that these drugs induce significant subjective and physiological effects that are transient, well tolerated, and apparently associated with therapeutic effects 13,15,30,31,44,47,50,51,53 .…”

Section: Safety and Toxicitymentioning

confidence: 99%

“…Furthermore, it is known that DMT act as an agonist at 5-HT 1A receptors 8,70 . The activation of 5-H 1A receptors may be in the basis of neurogenesis in the hippocampus and in the prefrontal cortex and its activation seems to be in the basis of the antidepressant effects of antidepressive drugs 71 .…”

Section: Suggestions For Future Researchmentioning

confidence: 99%

See 4 more Smart Citations

Ayahuasca: what mental health professionals need to know

Santos

Bouso²,

Hallak

2017

Arch. Clin. Psychiatry (São Paulo)

View full text Add to dashboard Cite

Background: Ayahuasca is a psychoactive ethnobotanical concoction that has been used for decades by indigenous groups of the Northwestern Amazon and by syncretic religious organizations for ritual and therapeutic purposes. In the last two decades, it is being used worldwide in evolving practices. Ayahuasca seem to therapeutic effects, but controlled studies are lacking. Moreover, its safety and toxicity are not completely understood. Objectives: To present an overview of the effects of ayahuasca based on the most recent human studies. Methods: Narrative review. Results: Ayahuasca administration in controlled settings appears to be safe from a subjective and physiological perspective, with few adverse reactions being reported. More frequent adverse reactions occur in non-controlled settings. Prolonged psychotic reactions are rare and seem to occur especially in susceptible individuals. Ayahuasca showed antidepressive, anxiolytic, and antiaddictive effects in animal models, observational studies, and in open-label and controlled studies. Discussion: Ayahuasca administration in controlled settings appear to be safe. Moreover, ayahuasca seem to have therapeutic effects for treatment-resistant psychiatric disorders that should be further investigated in randomized controlled clinical trials. However, medical complications and cases of prolonged psychotic reactions have been reported, and people with personal or family history of psychotic disorders should avoid ayahuasca intake.

show abstract

Section: Limitations Of the Studiesmentioning

confidence: 60%

Section: Botany Chemistry and Mechanism Of Actionmentioning

confidence: 99%

Section: Botany Chemistry and Mechanism Of Actionmentioning

confidence: 99%

Section: Safety and Toxicitymentioning

confidence: 99%

Section: Suggestions For Future Researchmentioning

confidence: 99%

See 3 more Smart Citations

Ayahuasca: what mental health professionals need to know

Santos

Bouso²,

Hallak

2017

Arch. Clin. Psychiatry (São Paulo)

View full text Add to dashboard Cite

show abstract

Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder

Davis

Barrett²,

May³

et al. 2021

JAMA Psychiatry

823

688

View full text Add to dashboard Cite

show abstract

Psychedelics in Psychiatry—Keeping the Renaissance From Going Off the Rails

Yaden

Griffiths

2021

JAMA Psychiatry

View full text Add to dashboard Cite

There is a resurgence, some say renaissance, of clinical research on psychedelic substances after decades of dormancy. Recent studies have produced findings suggesting psychedelics may demonstrate substantial efficacy for serious psychiatric conditions such as mood and substance use disorders. As a result, ongoing clinical trials with the psychedelic psilocybin have been given the Breakthrough Therapy designation by the US Food and Drug Administration that could result in medical approval for major depressive disorder and/or treatmentresistant depression.This new period of psychedelic research, ongoing since at least 2006, has now lasted for about the same length of time as psychedelic research in the 1950s and 1960s did before it ground to a halt. As contemporary psychedelic research results accrue, the field may be facing a fork in the road to clinical applications. One path forward allows for the same kinds of exuberance, utopian thinking, and uneven clinical approaches that contributed to ending the previous period of research. Combined with the contemporary tendency to politicize science, the possibility of a repeat of the 1960s represents a significant concern. Another path forward, a more careful and systematic one, involves the appropriate integration of psychedelic treatments into existing evidence-based psychiatric paradigms such as psychotherapy and pharmacotherapy.This Viewpoint offers perspectives on how the psychedelic research renaissance can stay on the path that leads to the integration of these medications into the standard of care rather than recapitulating the ethical and sociopolitical problems that led to the previous period of research going off the rails.

show abstract

Psychedelics

Cited by 1,214 publications

References 589 publications

Ayahuasca: what mental health professionals need to know

Ayahuasca: what mental health professionals need to know

Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder

Psychedelics in Psychiatry—Keeping the Renaissance From Going Off the Rails

Contact Info

Product

Resources

About